Study identifies potential target for reversing drug resistance in ovarian cancer

For the 314,000 people diagnosed with ovarian cancer each year, hope often comes in the form of platinum-based drugs such as cisplatin.

Phase one trial explores novel immunotherapy for breast cancer

A groundbreaking phase one clinical trial exploring a novel cell-based immunotherapy for breast cancer has been accepted for publication in JAMA Oncology.

December 6, 2024

AstraZeneca CEO reaffirms commitment to China following executive’s detention

NEW YORK — AstraZeneca is not backing away from China despite an investigation into its president of China operations. As the company reported its third-quarter

November 13, 2024

Santhera and Catalyst to market DMD drug vamorolone in North America – Pharmaceutical Technology

Santhera plan to repay its debt of CHF 29m ($33.8m) to Highbridge Capital and fund the pre-commercialization and launch of vamorolone in Europe. Image Credit:

July 19, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.